Scholar Rock Holding Corporation EBITDA 2011-2026 | SRRK

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Scholar Rock Holding Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-250 M	-168 M	-131 M	-127 M	-85.4 M	-53.2 M	-49.9 M	-24.4 M	-15.6 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-15.6 M	-250 M	-101 M

Quarterly EBITDA Scholar Rock Holding Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-76.7 M	-	-	-	-57.8 M	-	-	-	-39.8 M	-	-41.6 M	-41.7 M	-6.18 M	-	-35.2 M	-29 M	-26.6 M	-	-22.4 M	-18.7 M	-17.3 M	-	-16.2 M	-12.8 M	-11.4 M	-	-10.7 M	-14.5 M	-8.84 M	-	-5.44 M	-5.56 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-5.44 M	-76.7 M	-24.9 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Aptorum Group Limited APM	1.19 M	$ 0.84	2.78 %	$ 4.58 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Adagene ADAG	-35.2 M	$ 2.95	10.3 %	$ 166 M	China
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Amarin Corporation plc AMRN	-67.4 M	$ 15.08	2.24 %	$ 6.15 B	Irlanda
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.51	-1.68 %	$ 8.45 B	Australia
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Aptose Biosciences APTO	32 K	-	-45.71 %	$ 1.2 M	Canada
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Athira Pharma ATHA	-99.9 M	-	-	$ 269 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Brickell Biotech BBI	-6.32 M	-	-5.38 %	$ 6.06 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Ascendis Pharma A/S ASND	-452 M	$ 222.25	0.1 %	$ 5 B	Danmark
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	15.3 B	$ 109.88	-0.42 %	$ 27.2 B	Germany
Arena Pharmaceuticals ARNA	-620 M	-	-6.81 %	$ 3.04 B	USA
BeiGene, Ltd. BGNE	-396 M	-	0.49 %	$ 251 B	Cayman-islands
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA
Burford Capital Limited BUR	242 M	$ 9.21	2.56 %	$ 1.48 B	Britain
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Athersys ATHX	-85.6 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Baudax Bio BXRX	-56.6 M	-	0.59 %	$ 63 K	USA
Cabaletta Bio CABA	-73.2 M	$ 2.64	7.99 %	$ 3.08 M	USA
Can-Fite BioPharma Ltd. CANF	-10.1 M	$ 4.4	2.8 %	$ 9.57 B	Israel
Calithera Biosciences CALA	-115 M	-	-10.95 %	$ 876 K	USA
Autolus Therapeutics plc AUTL	-234 M	$ 1.44	-1.37 %	$ 367 M	Britain
Amneal Pharmaceuticals AMRX	312 M	$ 14.79	1.83 %	$ 4.57 B	USA
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA